This page shows the latest molnupiravir news and features for those working in and with pharma, biotech and healthcare.
Lagevrio (molnupiravir) is already approved or authorised to treat certain adults who have been diagnosed with COVID-19 in several markets, including the US, UK and China, but is not authorised
Those not recommended at this stage are Regenerons’ casirivimab and imdevimab, Merck and Ridgeback’s molnupiravir, GSK and Vir Biotechnology’s sotrovimab, as well as Gilead's remdesivir and AstraZeneca’s ... Molnupiravir and remdesivir are not
Merck &Co – known as MSD outside the US and Canada – and Ridgeback Biotherapeutics have announced that approximately 3.1 million courses of its investigational oral antiviral COVID-19 treatment, molnupiravir, have ... Alongside the most recent US
The statement notes that while restrictions have been made on Regeneron and Lilly treatments at this time, there are still several therapy options, including Paxlovid, sotrovimab, Veklury (remdesivir) and molnupiravir, that
The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next. ... Oral medications like molnupiravir and Paxlovid are significantly more convenient than the
Merck’s Lagevrio (molnupiravir) -3CL protease inhibitor, approved in the UK last week, was originally developed to treat influenza.
More from news
Approximately 3 fully matching, plus 15 partially matching documents found.
No results were found
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...